WuXi Biologics (Cayman) Inc.

WXIBFOTCHealthcare● Active

$4.40

+$0.00(+0.00%)

Market Cap$18.2B

P/E Ratio—

52W High$5.606

52W Low$2.85

Avg Volume383

Open$4.40

Beta0.56

Overview

WuXi Biologics (Cayman) Inc. (WXIBF) Revenue

Annual & quarterly revenue history · segment & region breakdown

WXIBF · revenue · updated Jun 10, 2026

Core revenue metrics

Trailing 12 months

WuXi Biologics (Cayman) Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue

$0.00B

4-quarter sum · USD

YoY growth

+0.00%

vs FY —

Price / sales

—

mktCap ÷ TTM rev

Revenue per day

—

Est. TTM ÷ 365

Revenue / employee

$0K

12575 employees

—

5Y CAGR

—

Fiscal year end

Dec 31

Currency

USD · GAAP

Filing

10-K / 10-Q

Source: FMP · WuXi Biologics (Cayman) Inc. SEC filings · GAAPUpdated: 2026-06-10

Revenue trend

– · Annual

YoY revenue growth %

revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year end	Revenue	Change	Growth

WXIBF revenue by year · WXIBF revenue history · WXIBF annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income WuXi Biologics (Cayman) Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

WuXi Biologics (Cayman) Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from WuXi Biologics (Cayman) Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Price history Financial statements Forecast

Frequently asked questions

WXIBF revenue · 4 questions

WXIBF's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

WXIBF revenueWXIBF annual revenuewhat is WXIBF revenueWXIBF TTM revenue

▸ Source: FMP · WuXi Biologics (Cayman) Inc. SEC filings · GAAP · WuXi Biologics (Cayman) Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026